US RNA-focussed biotech Avidity Biosciences (Nasdaq: RNA) saw is shares close up more than 12% at $46.95 on Friday, after it announced positive AOC 1044 5mg/kg data demonstrated unsurpassed delivery of phosphorodiamidate morpholino oligomers (PMO) concentrations to skeletal muscle in Duchenne muscular dystrophy (DMD) patients.
Avidity also announced delpacibart zotadirsen as the approved international non-proprietary name of AOC 1044, abbreviated as del-zota.
In the Phase I/II EXPLORE44 study, del-zota demonstrated:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze